Valeo Pharma Inc. Stock price Canadian Securities Exchange
Equities
VPH
CA91915B1085
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 CAD | -.--% | +1.54% | -10.81% |
Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
Mar. 15 | Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024 |
Sales 2024 * | 61M 44.88M | Sales 2025 * | 75.83M 55.79M | Capitalization | 15.79M 11.61M |
---|---|---|---|---|---|
Net income 2024 * | -18M -13.24M | Net income 2025 * | -12M -8.83M | EV / Sales 2024 * | 1.12 x |
Net Debt 2024 * | 52.53M 38.65M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.21 x |
P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-1.23
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.77% |
Latest transcript on Valeo Pharma Inc.
Managers | Title | Age | Since |
---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | Nov. 19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 18-07-24 |
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Marc Léger
BRD | Director/Board Member | 65 | 22-04-26 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.66% | 210B | |
+0.98% | 210B | |
-6.71% | 201B | |
-3.51% | 157B |
- Stock
- Equities
- Stock Valeo Pharma Inc.
- Stock Valeo Pharma Inc. - Canadian Securities Exchange